{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T18:38:58Z","timestamp":1775068738762,"version":"3.50.1"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T00:00:00Z","timestamp":1660348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This multicenter, retrospective study evaluated the effectiveness of add-on methotrexate (MTX) or iguratimod (IGU) in patients with rheumatoid arthritis exhibiting an inadequate response to Janus kinase inhibitors (JAKis).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Forty-five patients were treated with new additional MTX (n\u2009=\u200922) or IGU (n\u2009=\u200923) and followed for 6\u2009months. Patients\u2019 background is as follows: age, 59.2\u2009years; disease activity score of 28 joints with C-reactive protein (DAS28-CRP), 3.4; clinical disease activity index, 15.7; biological disease-modifying antirheumatic drug (DMARD)-switched cases, 77.8%; first JAKi cases, 95.6%; and JAKi treatment: tofacitinib (n\u2009=\u200925), baricitinib (n\u2009=\u200917), upadacitinib (n\u2009=\u20092), and peficitinib (n\u2009=\u20091) for 9.6\u2009months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Thirty-five patients continued the combination therapy for 6\u2009months without a significant change in concomitant glucocorticoid or other conventional synthetic DMARDs. DAS28-CRP (MTX, 3.6 to 2.6, p\u2009&amp;lt;\u20090.05; IGU, 3.3 to 2.1, p\u2009&amp;lt;\u20090.001) and clinical disease activity index (MTX, 16.7 to 8.8, p\u2009&amp;lt;\u20090.05; IGU, 14.6 to 6.5, p\u2009&amp;lt;\u20090.01) improved significantly from baseline. Using the 2019 European League Against Rheumatism criteria, 45.4% (MTX) and 39.1% (IGU) achieved moderate or good response and 40.9% (MTX) and 39.1% (IGU) achieved American College of Rheumatology 20% improvement criteria.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Adding MTX or IGU to inadequate responders of JAKi can be considered as a complementary treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roac092","type":"journal-article","created":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T05:37:03Z","timestamp":1660369023000},"page":"690-699","source":"Crossref","is-referenced-by-count":1,"title":["Add-on effectiveness of methotrexate or iguratimod in patients with rheumatoid arthritis exhibiting an inadequate response to Janus kinase inhibitors: The ANSWER cohort study"],"prefix":"10.1093","volume":"33","author":[{"given":"Kosuke","family":"Ebina","sequence":"first","affiliation":[{"name":"Department of Musculoskeletal Regenerative Medicine, Osaka University Graduate School of Medicine , Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Hirano","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Nishinomiya Municipal Hospital , Hyogo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine , Osaka, Japan"},{"name":"Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University , Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasutaka","family":"Okita","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine , Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Etani","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine , Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Hirao","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine , Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Health Information Management, Kurashiki Sweet Hospital , Okayama, Japan"},{"name":"Department of Advanced Medicine for Rheumatic diseases, Graduate School of Medicine, Kyoto University , Kyoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motomu","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Advanced Medicine for Rheumatic diseases, Graduate School of Medicine, Kyoto University , Kyoto, Japan"},{"name":"Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine , Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Murata","sequence":"additional","affiliation":[{"name":"Department of Advanced Medicine for Rheumatic diseases, Graduate School of Medicine, Kyoto University , Kyoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Onishi","sequence":"additional","affiliation":[{"name":"Department of Advanced Medicine for Rheumatic diseases, Graduate School of Medicine, Kyoto University , Kyoto, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadao","family":"Jinno","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine , Hyogo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryota","family":"Hara","sequence":"additional","affiliation":[{"name":"Rheumatology Clinic and Department of Orthopaedic Surgery, Nara Medical University , Nara, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonsu","family":"Son","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Kansai Medical University , Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Amuro","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, Kansai Medical University , Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Kotani","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University , Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Shiba","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University , Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Katayama","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Osaka Red Cross Hospital , Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Information Technology Center, Wakayama Medical University , Wakayama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kumanogoh","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine , Osaka, Japan"},{"name":"Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University , Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine , Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Nakata","sequence":"additional","affiliation":[{"name":"Department of Health and Sport Sciences, Osaka University Graduate School of Medicine , Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,8,13]]},"reference":[{"key":"2023070502120636000_R1","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"2023070502120636000_R2","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023070502120636000_R3","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1007\/s10067-021-05609-7","article-title":"Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study","volume":"40","author":"Ebina","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2023070502120636000_R4","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1007\/s10067-020-05015-5","article-title":"Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis \u2013 the ANSWER cohort study","volume":"39","author":"Ebina","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2023070502120636000_R5","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-02232-w","article-title":"Drug retention of 7 biologics and tofacitinib in biologics-naive and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study","volume":"22","author":"Ebina","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2023070502120636000_R6","first-page":"473","article-title":"Methotrexate in rheumatoid arthritis","volume":"58","author":"Swierkot","year":"2006","journal-title":"Pharmacol Rep"},{"key":"2023070502120636000_R7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00073","article-title":"Iguratimod as a new drug for rheumatoid arthritis: current landscape","volume":"11","author":"Xie","year":"2020","journal-title":"Front Pharmacol"},{"key":"2023070502120636000_R8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0165-5728(98)00056-3","article-title":"A new anti-rheumatic drug, T-614, effectively suppresses the development of autoimmune encephalomyelitis","volume":"89","author":"Aikawa","year":"1998","journal-title":"J Neuroimmunol"},{"key":"2023070502120636000_R9","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/PL00000291","article-title":"An anti-rheumatic agent T-614 inhibits NF-kappaB activation in LPS- and TNF-alpha-stimulated THP-1 cells without interfering with IkappaBalpha degradation","volume":"51","author":"Aikawa","year":"2002","journal-title":"Inflamm Res"},{"key":"2023070502120636000_R10","doi-asserted-by":"publisher","DOI":"10.1186\/ar2554","article-title":"T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis","volume":"10","author":"Du","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"2023070502120636000_R11","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/S0022-2143(99)90186-5","article-title":"Inhibitory effect of a new anti-rheumatic drug T-614 on costimulatory molecule expression, cytokine production, and antigen presentation by synovial cells","volume":"133","author":"Kawakami","year":"1999","journal-title":"J Lab Clin Med"},{"key":"2023070502120636000_R12","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1248\/bpb1978.15.649","article-title":"Pharmacological studies on 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one (T-614), a novel antiinflammatory agent. 4th communication: inhibitory effect on the production of interleukin-1 and interleukin-6","volume":"15","author":"Tanaka","year":"1992","journal-title":"J Pharmacobiodyn"},{"key":"2023070502120636000_R13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00011-007-6022-9","article-title":"Effect of iguratimod and other anti-rheumatic drugs on adenocarcinoma colon 26-induced cachexia in mice","volume":"56","author":"Tanaka","year":"2007","journal-title":"Inflamm Res"},{"key":"2023070502120636000_R14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-04075-0","article-title":"Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study","volume":"12","author":"Ebina","year":"2022","journal-title":"Sci Rep"},{"key":"2023070502120636000_R15","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02496-w","article-title":"Comparison of the drug retention and reasons for discontinuation of tumor necrosis factor inhibitors and interleukin-6 inhibitors in Japanese patients with elderly-onset rheumatoid arthritis-the ANSWER cohort study","volume":"23","author":"Jinno","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2023070502120636000_R16","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s00296-021-04862-y","article-title":"Comparison of efficacy between anti-IL-6 receptor antibody and other biological disease-modifying antirheumatic drugs in the patients with rheumatoid arthritis who have knee joint involvement: the ANSWER cohort, retrospective study","volume":"41","author":"Maeda","year":"2021","journal-title":"Rheumatol Int"},{"key":"2023070502120636000_R17","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1093\/mr\/roab043","article-title":"The real-world effectiveness of anti-RANKL antibody denosumab on the clinical fracture prevention in patients with rheumatoid arthritis: the ANSWER cohort study","volume":"32","author":"Murata","year":"2021","journal-title":"Mod Rheumatol"},{"key":"2023070502120636000_R18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/03009742.2021.1947005","article-title":"Favorable clinical response and drug retention of anti-IL-6 receptor inhibitor in rheumatoid arthritis with high CRP levels: the ANSWER cohort study","author":"Nakayama","year":"2021","journal-title":"Scand J Rheumatol"},{"key":"2023070502120636000_R19","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1053\/j.ajkd.2021.02.338","article-title":"The association of disease activity and estimated GFR in patients with rheumatoid arthritis: findings from the ANSWER study","volume":"78","author":"Onishi","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"2023070502120636000_R20","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"2023070502120636000_R21","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2023070502120636000_R22","first-page":"939","article-title":"Guidelines for the management of rheumatoid arthritis","volume":"74","author":"Kawahito","year":"2016","journal-title":"Nihon Rinsho"},{"key":"2023070502120636000_R23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14397595.2018.1486939","article-title":"The add-on effectiveness and safety of iguratimod in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab","volume":"29","author":"Ebina","year":"2018","journal-title":"Mod Rheumatol"},{"key":"2023070502120636000_R24","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1080\/14397595.2016.1181315","article-title":"The efficacy and safety of additional administration of tacrolimus in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab","volume":"27","author":"Kaneshiro","year":"2017","journal-title":"Mod Rheumatol"},{"key":"2023070502120636000_R25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/14397595.2018.1472358","article-title":"Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis","volume":"29","author":"Kameda","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2023070502120636000_R26","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/art.1780390105","article-title":"Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization\/International League Against Rheumatism Criteria","volume":"39","author":"van Gestel","year":"1996","journal-title":"Arthritis Rheum"},{"key":"2023070502120636000_R27","first-page":"S100","article-title":"The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2023070502120636000_R28","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"2023070502120636000_R29","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"2023070502120636000_R30","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000742","article-title":"Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib","volume":"5","author":"Bird","year":"2019","journal-title":"RMD Open"},{"key":"2023070502120636000_R31","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/czhc93","article-title":"Prediction of the intolerance or non-responder to Janus kinase inhibitors in patients with rheumatoid arthritis: a preliminary retrospective study with integrative cluster analysis","author":"Sugawara","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"2023070502120636000_R32","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/151626","article-title":"Anti-cyclic citrullinated peptide antibodies and severity of interstitial lung disease in women with rheumatoid arthritis","volume":"2015","author":"Rocha-Munoz","year":"2015","journal-title":"J Immunol Res"},{"key":"2023070502120636000_R33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126211","article-title":"Role of JAK\/STAT in interstitial lung diseases; molecular and cellular mechanisms","volume":"22","author":"Montero","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2023070502120636000_R34","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104354","article-title":"Effects of biological and targeted synthetic DMARDs on bone loss in rheumatoid arthritis","volume":"147","author":"Orsolini","year":"2019","journal-title":"Pharmacol Res"},{"key":"2023070502120636000_R35","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1002\/art.40187","article-title":"The safety and immunogenicity of live zoster vaccination in patients with rheumatoid arthritis before starting tofacitinib: a randomized Phase II Trial","volume":"69","author":"Winthrop","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2023070502120636000_R36","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2023070502120636000_R37","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1002\/jcph.1795","article-title":"Differential binding of sarilumab and tocilizumab to IL-6Ralpha and effects of receptor occupancy on clinical parameters","volume":"61","author":"Xu","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"2023070502120636000_R38","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41584-020-0373-9","article-title":"Methotrexate and its mechanisms of action in inflammatory arthritis","volume":"16","author":"Cronstein","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2023070502120636000_R39","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.4049\/jimmunol.160.11.5213","article-title":"Adenovirus-mediated transfer of viral IL-10 gene inhibits murine collagen-induced arthritis","volume":"160","author":"Apparailly","year":"1998","journal-title":"J Immunol"},{"key":"2023070502120636000_R40","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.4049\/jimmunol.163.8.4546","article-title":"Adenoviral vector-mediated overexpression of IL-4 in the knee joint of mice with collagen-induced arthritis prevents cartilage destruction","volume":"163","author":"Lubberts","year":"1999","journal-title":"J Immunol"},{"key":"2023070502120636000_R41","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2023070502120636000_R42","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/214683","article-title":"Inhibitory effect of a novel antirheumatic drug T-614 on the IL-6-induced RANKL\/OPG, IL-17, and MMP-3 expression in synovial fibroblasts from rheumatoid arthritis patients","volume":"2015","author":"Wei","year":"2015","journal-title":"Biomed Res Int"},{"key":"2023070502120636000_R43","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000363","article-title":"Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study","volume":"3","author":"Takahashi","year":"2017","journal-title":"RMD Open"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roac092\/45596385\/roac092.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/4\/690\/50797301\/roac092.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/33\/4\/690\/50797301\/roac092.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T03:04:30Z","timestamp":1688526270000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/33\/4\/690\/6664276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,13]]},"references-count":43,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,8,13]]},"published-print":{"date-parts":[[2023,7,4]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roac092","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7,1]]},"published":{"date-parts":[[2022,8,13]]}}}